Table 1 .
From: Impact of uPA/PAI-1 and disseminated cytokeratin-positive cells in breast cancer
Complete collection n = 480 (100%) | Positive dCK+ cells n = 110 (23%) | Negative dCK+ cells n = 370 (77%) | UPA pos. n = 220 (46%) | UPA neg n = 260 (54%) | PAI 1 pos. n = 326 (68%) | PAI 1 neg. n = 154 (32%) | |
|---|---|---|---|---|---|---|---|
Age | |||||||
< 51 years | 115 (24%) | 27 (25%) | 88 (24%) | 50 (23%) | 65 (25%) | 78 (24%) | 37 (24%) |
51–58 years | 76 (16%) | 19 (17%) | 57 (15%) | 39 (18%) | 37 (14%) | 50 (15%) | 26 (17%) |
59–66 years | 129 (27%) | 28 (25%) | 101 (27%) | 58 (26%) | 71 (27%) | 84 (26%) | 45 (29%) |
67–75 years | 111 (23%) | 25 (23%) | 86 (23%) | 51 (23%) | 60 (23%) | 78 (24%) | 33 (21%) |
> 75 years | 49 (10%) | 11 (10%) | 38 (10%) | 22 (10%) | 27 (10%) | 36 (11%) | 13 (8%) |
p = 0.9 n.s | p = 0.8 n.s. | p = 0.8 n.s. | |||||
Tumor Size | |||||||
pT1 | 244 (51%) | 52 (47%) | 192 (52%) | 116 (53%) | 128 (49%) | 166 (51%) | 78 (51%) |
pT2 | 191 (40%) | 45 (41%) | 146 (39%) | 88 (40%) | 103 (40%) | 133 (41%) | 58 (38%) |
pT3 | 33 (7%) | 11 (10%) | 22 (6%) | 11 (5%) | 22 (8%) | 20 (6%) | 13 (8%) |
pT4 | 11 (2%) | 1 (1%) | 10 (3%) | 4 (2%) | 7 (3%) | 7 (2%) | 4 (3%) |
unknown | 1 (0%) | 1 (1%) | 0 (0%) | 1 (0%) | 0 (0%) | 0 (0%) | 1 (1%) |
p = 0.1 n.s. | p = 0.4 n.s. | p = 0.5 n.s. | |||||
Grading | |||||||
G1 | 45 (9%) | 11 (10%) | 34 (9%) | 14 (6%) | 31 (12%) | 31 (10%) | 14 (9%) |
G2 | 275 (57%) | 61 (55%) | 214 (58%) | 111 (50%) | 164 (63%) | 172 (53%) | 103 (67%) |
G3 | 157 (33%) | 37 (34%) | 120 (32%) | 94 (43%) | 63 (24%) | 122 (37%) | 35 (23%) |
unknown | 3 (1%) | 1 (1%) | 2 (1%) | 1 (0%) | 2 (1%) | 1 (0%) | 2 (1%) |
p = 0.9 n.s | p < 0.001 sign. | p < 0.007 sign. | |||||
Nodal Status | |||||||
pN0 | 249 (52%) | 53 (48%) | 196 (53%) | 112 (51%) | 137 (53%) | 171 (52%) | 78 (51%) |
pN1 | 148 (31%) | 30 (27%) | 118 (32%) | 73 (33%) | 75 (29%) | 103 (32%) | 45 (29%) |
pN2 | 47 (10%) | 10 (9%) | 37 (10%) | 22 (10%) | 25 (10%) | 29 (9%) | 18 (12%) |
pN3 | 29 (6%) | 15 (14%) | 14 (4%) | 10 (5%) | 19 (7%) | 19 (6%) | 10 (6%) |
unknown | 7 (1%) | 2 (2%) | 5 (1%) | 3 (1%) | 4 (2%) | 4 (1%) | 3 (2%) |
p < 0.005 sign. | p = 0.6 n.s. | p = 0.8 n.s. | |||||
UICC-stage | |||||||
stage I | 147 (31%) | 33 (30%) | 114 (31%) | 61 (28%) | 86 (33%) | 95 (29%) | 52 (34%) |
stage IIA | 167 (35%) | 30 (27%) | 137 (37%) | 84 (38%) | 83 (32%) | 121 (37%) | 46 (30%) |
stage IIB | 68 (14%) | 15 (14%) | 53 (14%) | 32 (15%) | 36 (14%) | 45 (14%) | 23 (15%) |
stage IIIA | 46 (10%) | 10 (9%) | 36 (10%) | 22 (10%) | 24 (9%) | 29 (9%) | 17 (11%) |
stage IIIB | 2 (0%) | 1 (1%) | 1 (0%) | 0 (0%) | 2 (1%) | 2 (1%) | 0 (0%) |
stage IIIC | 27 (6%) | 11 (10%) | 16 (4%) | 9 (4%) | 18 (7%) | 17 (5%) | 10 (6%) |
stage IV | 21 (4%) | 9 (8%) | 12 (3%) | 11 (5%) | 10 (4%) | 16 (5%) | 5 (3%) |
unknown | 2 (0%) | 1 (1%) | 1 (0%) | 1 (0%) | 1 (0%) | 1 (0%) | 1 (1%) |
p = 0.038 sign.* | p = 0.352 n.s.* | p = 0.437 n.s.* | |||||
Chemotherapie | |||||||
yes | 291 (61%) | 65 (59%) | 226 (61%) | 149 (68%) | 142 (55%) | 210 (64%) | 81 (53%) |
no | 145 (30%) | 36 (33%) | 109 (29%) | 52 (24%) | 93 (36%) | 84 (26%) | 61 (40%) |
unknown | 44 (9%) | 9 (8%) | 35 (9%) | 19 (9%) | 25 (10%) | 32 (10%) | 12 (8%) |
p = 0.7 n.s. | p < 0.01 sign. | p < 0.009 sign. | |||||
Estrogen | |||||||
negative | 57 (12%) | 14 (13%) | 43 (12%) | 35 (16%) | 22 (8%) | 46 (14%) | 11 (7%) |
positive | 419 (87%) | 94 (85%) | 325 (88%) | 183 (83%) | 236 (91%) | 278 (85%) | 141 (92%) |
unknown | 4 (1%) | 2 (2%) | 2 (1%) | 2 (1%) | 2 (1%) | 2 (1%) | 2 (1%) |
p = 0.4 n.s. | p = 0.04 sign. | p = 0.06 n.s. | |||||
Progesteron | |||||||
negative | 63 (13%) | 15 (14%) | 48 (13%) | 40 (18%) | 23 (9%) | 52 (16%) | 11 (7%) |
positive | 413 (86%) | 93 (85%) | 320 (86%) | 178 (81%) | 235 (90%) | 272 (83%) | 141 (92%) |
unknown | 4 (1%) | 2 (2%) | 2 (1%) | 2 (1%) | 2 (1%) | 2 (1%) | 2 (1%) |
p = 0.4 n.s. | p = 0.01 sign. | p = 0.023 sign. | |||||
HER2-Status | |||||||
negative | 362 (75%) | 82 (75%) | 280 (76%) | 158 (72%) | 204 (78%) | 236 (72%) | 126 (82%) |
positive | 107 (22%) | 26 (24%) | 81 (22%) | 57 (26%) | 50 (19%) | 84 (26%) | 23 (15%) |
unknown | 11 (2%) | 2 (2%) | 9 (2%) | 5 (2%) | 6 (2%) | 6 (2%) | 5 (3%) |
p = 0.8 n.s. | p = 0.2 n.s. | p = 0.022 sign. | |||||